Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.

Zentalis Pharmaceuticals Inc.

The latest update is out from Zentalis Pharmaceuticals ( ($ZNTL) ). Effective May 22, 2026, Zentalis Pharmaceuticals expanded its board of director...

Zentalis Pharmaceuticals Expands Board, Appoints New Director

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Zentalis Pharmaceuticals today and set a price target of $10.00. Y. Maldonad...

Zentalis Pharmaceuticals (ZNTL) Receives a Buy from H.C. Wainwright

Zentalis Pharmaceuticals ( ($ZNTL) ) has issued an announcement. On May 21, 2026, Zentalis Pharmaceuticals reported Phase 1b MUIR trial data showin...

Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an announcement. On May 12, 2026, Zentalis Pharmaceuticals reported first-quarter 2026 results an...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ZNTL	$3.54	-1.12%	219.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ZNTL	$3.54	-1.1%	219.27K
3
4
5
6

ZNTL

ZNTL

Dividend Overview

Get Zentalis Pharmaceuticals Inc. Data in Excel

Get Zentalis Pharmaceuticals Inc. Data in Excel